U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H15N3O2S
Molecular Weight 265.331
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALBENDAZOLE

SMILES

CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2

InChI

InChIKey=HXHWSAZORRCQMX-UHFFFAOYSA-N
InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)

HIDE SMILES / InChI
Molecular Formula C12H15N3O2S
Molecular Weight 265.331
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11386684

ALBENZA (albendazole) is an orally administered anthelmintic drug. Chemically, it is methyl 5¬ (propylthio)-2-benzimidazolecarbamate, is indicated to treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. In addition, treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. Albendazole binds to the colchicine-sensitive site of β-tubulin inhibiting their polymerization into microtubules. The decrease in microtubules in the intestinal cells of the parasites decreases their absorptive function, especially the uptake of glucose by the adult and larval forms of the parasites, and depletes glycogen storage. Insufficient glucose results in insufficient energy for the production of adenosine trisphosphate (ATP) and the parasite eventually dies. Albendazole developed in 1975. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just >1% . Albendazole's unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92%, for A. duodenale in 23 studies and 75% for N. americanus in 30 studies), A. lumbricoides (95% in 64 studies), T. trichiura (48% in 57 studies), E. vermicularis (98% in 27 studies), S. stercoralis (62% in 19 studies), H. nana (68% in 11 studies), and Taenia spp. (85% in 7 studies).

CNS Activity

CNS Penetrant
2588
Curator's Comment: Albendazole penetrates blood–brain barrier, with concentrations in CSF reaching 50% of that found in plasma

Originator

Approval Year

1989
115
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
ALBENZA

Approved Use

ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. (1.1) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. (1.2) 1.1 Neurocysticercosis ALBENZA is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. 1.2 Hydatid Disease ALBENZA is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

Launch Date

1996
Curative
Approved
8583
ALBENZA

Approved Use

ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. (1.1) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. (1.2) 1.1 Neurocysticercosis ALBENZA is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. 1.2 Hydatid Disease ALBENZA is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
707.37 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE OXIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
39.61 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE SULFONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1310 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALBENDAZOLE OXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3713.96 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE OXIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
284.55 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE SULFONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.43 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE OXIDE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.91 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12784319
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALBENDAZOLE SULFONE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALBENDAZOLE OXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf
400 mg 2 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ALBENDAZOLE OXIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Doses

Doses

DosePopulationAdverse events​
1200 mg 2 times / day multiple, oral
MTD
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19904538
unhealthy, 25–81
Health Status: unhealthy
Age Group: 25–81
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19904538
Disc. AE: Neutropenic sepsis...
AEs leading to
discontinuation/dose reduction:
Neutropenic sepsis (grade 5, 11%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19904538
3200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 3200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3200 mg, 1 times / day
Sources:
https://books.google.ru/books?id=0imPNTTuyysC&pg=PA57&lpg=PA57&dq=albendazole+3200+mg/day&source=bl&ots=puJwTcRNB9&sig=ACfU3U0fo-4zPrZjg81VYFlMRRe9brtv2w&hl=ru&sa=X&ved=2ahUKEwiV7_Dagd_tAhVL-yoKHfNGCfwQ6AEwCHoECAUQAg#v=onepage&q=albendazole%203200%20mg%2Fday&f=false
unhealthy, 38
Health Status: unhealthy
Age Group: 38
Sex: F
Sources:
https://books.google.ru/books?id=0imPNTTuyysC&pg=PA57&lpg=PA57&dq=albendazole+3200+mg/day&source=bl&ots=puJwTcRNB9&sig=ACfU3U0fo-4zPrZjg81VYFlMRRe9brtv2w&hl=ru&sa=X&ved=2ahUKEwiV7_Dagd_tAhVL-yoKHfNGCfwQ6AEwCHoECAUQAg#v=onepage&q=albendazole%203200%20mg%2Fday&f=false
Disc. AE: Parkinsonism aggravated...
AEs leading to
discontinuation/dose reduction:
Parkinsonism aggravated
Sources:
https://books.google.ru/books?id=0imPNTTuyysC&pg=PA57&lpg=PA57&dq=albendazole+3200+mg/day&source=bl&ots=puJwTcRNB9&sig=ACfU3U0fo-4zPrZjg81VYFlMRRe9brtv2w&hl=ru&sa=X&ved=2ahUKEwiV7_Dagd_tAhVL-yoKHfNGCfwQ6AEwCHoECAUQAg#v=onepage&q=albendazole%203200%20mg%2Fday&f=false
16 g single, oral
Overdose
Dose: 16 g
Route: oral
Route: single
Dose: 16 g
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Disc. AE: Granulocytopenia, Pancytopenia...
Other AEs: Bone marrow depression, Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Granulocytopenia (grade 5)
Pancytopenia (grade 5)
Other AEs:
Bone marrow depression
Aplastic anemia
Agranulocytosis
Disorder fetal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Disc. AE: Leukopenia...
AEs leading to
discontinuation/dose reduction:
Leukopenia (0.7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Disc. AE: Hepatic dysfunction NOS...
AEs leading to
discontinuation/dose reduction:
Hepatic dysfunction NOS (3.8%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Neutropenic sepsis grade 5, 11%
Disc. AE
1200 mg 2 times / day multiple, oral
MTD
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19904538
unhealthy, 25–81
Health Status: unhealthy
Age Group: 25–81
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/19904538
Parkinsonism aggravated Disc. AE
3200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 3200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3200 mg, 1 times / day
Sources:
https://books.google.ru/books?id=0imPNTTuyysC&pg=PA57&lpg=PA57&dq=albendazole+3200+mg/day&source=bl&ots=puJwTcRNB9&sig=ACfU3U0fo-4zPrZjg81VYFlMRRe9brtv2w&hl=ru&sa=X&ved=2ahUKEwiV7_Dagd_tAhVL-yoKHfNGCfwQ6AEwCHoECAUQAg#v=onepage&q=albendazole%203200%20mg%2Fday&f=false
unhealthy, 38
Health Status: unhealthy
Age Group: 38
Sex: F
Sources:
https://books.google.ru/books?id=0imPNTTuyysC&pg=PA57&lpg=PA57&dq=albendazole+3200+mg/day&source=bl&ots=puJwTcRNB9&sig=ACfU3U0fo-4zPrZjg81VYFlMRRe9brtv2w&hl=ru&sa=X&ved=2ahUKEwiV7_Dagd_tAhVL-yoKHfNGCfwQ6AEwCHoECAUQAg#v=onepage&q=albendazole%203200%20mg%2Fday&f=false
Agranulocytosis
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Aplastic anemia
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Bone marrow depression
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Disorder fetal
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Granulocytopenia grade 5
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Pancytopenia grade 5
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Leukopenia 0.7%
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Hepatic dysfunction NOS 3.8%
Disc. AE
400 mg 2 times / day multiple, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946
substrate
1193
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1741
FMO
34

CYP
303

FMO3
77

CYP1A2
1197

CYP2E1
729

CYP2A6
626

CYP2B6
776

CYP2C8
810

CYP2C19
1119

P-gp
2052

BCRP
697

MRP2
252

CYP2J2
71
CYP1A
59
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1932
 no
CYP1A
122
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2A6
626
 inconclusive
CYP2B6
776
 inconclusive
CYP2C19
1119
 inconclusive
CYP2C8
810
 inconclusive
BCRP
697
 no
CYP2C9
1193
 no
CYP2E1
729
 no
MRP2
252
 no
MRP2
252
 no
ALBENDAZOLE sulfoxide
1
P-gp
2052
 no
P-gp
2052
 no
ALBENDAZOLE sulfoxide
1
BCRP
697
 yes
ALBENDAZOLE sulfoxide
1
CYP
303
 yes
CYP1A2
1197
 yes
CYP2J2
71
 yes
CYP3A4
1946
 yes
FMO
34
 yes
FMO3
77
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:16664
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16664
ChemicalBook
CB0241320
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0241320
eMolecules
1985404
https://www.emolecules.com/cgi-bin/more?vid=1985404
eMolecules
31777221
https://www.emolecules.com/cgi-bin/more?vid=31777221
eMolecules
534226
https://www.emolecules.com/cgi-bin/more?vid=534226
MolPort
MolPort-000-726-929
https://www.molport.com/shop/molecule-link/MolPort-000-726-929
MolPort
MolPort-000-760-571
https://www.molport.com/shop/molecule-link/MolPort-000-760-571
MolPort
MolPort-001-932-918
https://www.molport.com/shop/molecule-link/MolPort-001-932-918
Selleck Chemicals
Albendazole(Albenza)
http://www.selleckchem.com/products/Albendazole(Albenza).html
ZINC
ZINC000017146904
http://zinc15.docking.org/substances/ZINC000017146904
PubMed

PubMed

TitleDatePubMed
Ivermectin treatment of a traveler who returned from Peru with cutaneous gnathostomiasis.
2001-08-15
Strongyloides stercoralis eggs in the stools during anticancer therapy.
2001-08-11
Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis.
2001-08-09
Retroperitoneal localization of hydatid cyst disease.
2001-08-09
[Orthopedic aspects of osseous echinococcosis--radiologic diagnosis, current surgery and drug therapy aspects].
2001-08-07
Microsporidiosis in the graft of a renal transplant recipient.
2001-08
Ocular and orbital cysticercosis.
2001-08
Gnathostomiasis.
2001-07-28
Integrated programme for control of geohelminths: a perspective.
2001-07-27
Proposed diagnostic criteria for neurocysticercosis.
2001-07-24
[Neurocysticercosis].
2001-07-19
Parasitic cysts of the liver - practical approach to diagnosis and differentiation.
2001-07-04
Cutaneous larva migrans contracted in England: a reminder.
2001-07
Anthelmintic resistance on goat farms in Georgia: efficacy of anthelmintics against gastrointestinal nematodes in two selected goat herds.
2001-06-28
Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract.
2001-06-19
Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome.
2001-06-15
Control of anthelmintic resistant endoparasites in a commercial sheep flock through parasite community replacement.
2001-06-12
Activity of oxyclozanide, nitroxynil, clorsulon and albendazole against adult triclabendazole-resistant Fasciola hepatica.
2001-06-09
Synthesis and hydrolytic stability studies of albendazole carrier prodrugs.
2001-06-04
Epidemiology of swine trichinellosis in China.
2001-06
Efficacy of flubendazole and albendazole against Trichinella spiralis in mice.
2001-06
Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes.
2001-06
Cerebral cysticercus granuloma associated with a subdural effusion.
2001-06
Pharmacokinetics of ricobendazole in calves.
2001-06
Treatment of ocular toxocariasis with albendazole.
2001-06
[Echinococcosis of the pelvic bone: four cases].
2001-06
[Vertebral hydatidosis: three case reports].
2001-06
Intestinal helminth infections, anaemia and labour productivity of female tea pluckers in Bangladesh.
2001-06
Seizure recurrence in children with focal seizures and single small enhancing computed tomographic lesions: prognostic factors on long-term follow-up.
2001-06
The management of liver hydatid cysts by percutaneous drainage.
2001-06
Late onset temporal lobe epilepsy with MRI evidence of mesial temporal sclerosis following acute neurocysticercosis: case report.
2001-06
An unusual cause of renal colic: hydatiduria.
2001-06
The effect of different anthelmintic treatment regimens combined with iron supplementation on the nutritional status of schoolchildren in KwaZulu-Natal, South Africa: a randomized controlled trial.
2001-05-18
Albendazole therapy and reduced decline in haemoglobin concentration during pregnancy (Sierra Leone).
2001-05-18
Albendazole versus placebo in treatment of echinococcosis.
2001-05-18
Cystic echinococcosis in semi-nomadic pastoral communities in north-west China.
2001-05-18
[Human microsporidiosis].
2001-05
Some aspects in the control of schistosomosis and soil-transmitted helminthosis in Yemeni children.
2001-05
Effect of ruminal microflora on the biotransformation of netobimin, albendazole, albendazole sulfoxide, and albendazole sulfoxide enantiomers in an artificial rumen.
2001-05
The epidemiology of gastrointestinal nematodes of dairy cattle in central Kenya.
2001-05
[Disseminated strongyloidiasis].
2001-04-28
Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle.
2001-04
Impact of iron supplementation and deworming on growth performance in preschool Beninese children.
2001-04
In vitro taurocholate-induced segmentation and clustering of Mesocestoides vogae (syn. corti) tetrathyridia (Cestoda)--inhibition byh cestocidal drugs.
2001-04
Comparative metabolism of albendazole and albendazole sulphoxide by different helminth parasites.
2001-04
Multispecific resistance of trichostrongyles to benzimidazoles in a goat herd in Germany.
2001-02
Optimising the benefits of anthelmintic treatment in children.
2001
Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia.
2001
Comparison of worm control strategies in grazing sheep in Denmark.
2001
Albendazole therapy in the treatment of hydatid liver disease.
2001
Patents

Patents

JP2007500004A
13

Sample Use Guides

In Vivo Use Guide
Patients weighing 60 kg or greater, 400 mg twice daily; less than 60 kg, 15 mg/kg/day in divided doses twice daily (maximum total daily dose 800 mg). Hydatid disease: 28-day cycle followed by 14-day albendazole-free interval for a total of 3 cycles. Neurocysticercosis: 8 to 30 days.
Route of Administration: Oral
In Vitro Use Guide
The antiproliferative effect of Albendazole (ABZ) on parent PTX-sensitive 1A9 and PTX-resistant sub-line 1A9PTX22 cells (human ovarian cancer)were compared to those induced by colchicine and paclitaxel (PTX). Cells were exposed to drugs for 3 days (colchicine) or 5 days (ABZ and PTX). The results demonstrate the inhibitory effect on 1A9 and 1A9PTX22 cells by ABZ (IC50=237 nM ± 3.65 and 351 nM ± 90 respectively).
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:46:00 GMT 2025
Edited
by admin
on Mon Mar 31 17:46:00 GMT 2025
Record UNII
F4216019LN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHYL 5-(PROPYLTHIO)BENZIMIDAZOL-2-YLCARBAMATE
Preferred Name English
ALBENDAZOLE
EP   GREEN BOOK   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
albendazole [INN]
Common Name English
ALBENDAZOLE [USP-RS]
Common Name English
ALBENDAZOLE [USAN]
Common Name English
ALBENZA
Brand Name English
SK&F 62979
Code English
ALBENDAZOLE [MI]
Common Name English
ZENTEL
Brand Name English
METHYL N-(5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)CARBAMATE
Systematic Name English
ALBENDAZOLE [WHO-IP]
Common Name English
ALBENDAZOLE [EP MONOGRAPH]
Common Name English
ALBENDAZOLE [USP MONOGRAPH]
Common Name English
ALBENDAZOLE [VANDF]
Common Name English
SK&F-62979
Code English
Methyl 5-(propylthio)-2-benzimidazolecarbamate
Common Name English
ALBENDAZOLE [JAN]
Common Name English
CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER
Common Name English
ALBENDAZOLE [HSDB]
Common Name English
ALBENDAZOLE [GREEN BOOK]
Common Name English
ESKAZOLE
Brand Name English
ALBENDAZOLE [MART.]
Common Name English
Albendazole [WHO-DD]
Common Name English
ALBENDAZOLE [ORANGE BOOK]
Common Name English
ALBENDAZOLUM [WHO-IP]
Common Name English
ANDAZOL
Brand Name English
NSC-220008
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 94295
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 6.1.1
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
CFR 21 CFR 520.38A
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
WHO-ATC P02CA03
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
CFR 21 CFR 520.38
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
NCI_THESAURUS C250
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
WHO-VATC QP52AC11
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
CFR 21 CFR 520.38B
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
CFR 21 CFR 556.34
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
FDA ORPHAN DRUG 94195
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
LIVERTOX NBK548360
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
NDF-RT N0000175481
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 6.1.2
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
Code System Code Type Description
DAILYMED
F4216019LN
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
CHEBI
16664
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
FDA UNII
F4216019LN
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
MERCK INDEX
m1473
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY Merck Index
RS_ITEM_NUM
1012553
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
NSC
220008
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
HSDB
7444
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
PUBCHEM
2082
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
RXCUI
430
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB00518
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
SMS_ID
100000087712
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
CAS
54965-21-8
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
WIKIPEDIA
ALBENDAZOLE
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ALBENDAZOLE
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY Description: A white or almost white powder. Solubility: Practically insoluble in water; soluble in glacial acetic acid R; slightly soluble in acetone R, very slightly soluble in ethanol (~750 g/l) TS. Category: Anthelminthic. Storage: Albendazole should be kept in a well-closed container, protected from light. Additional information: Melting temperature, about 210?C, with decomposition. Requirement: Albendazole contains not less than 98.0% and not more than 101.0% of C12H15N3O2S, calculated with reference to the dried substance.
MESH
D015766
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
NDF-RT
N0000191624
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY Cytochrome P450 1A Inducers [MoA]
NCI_THESAURUS
C47384
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
INN
3967
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
EVMPD
SUB05295MIG
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
ChEMBL
CHEMBL1483
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
ALANWOOD
albendazole
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
DRUG CENTRAL
103
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
EPA CompTox
DTXSID0022563
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
LACTMED
Albendazole
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
ECHA (EC/EINECS)
259-414-7
Created by admin on Mon Mar 31 17:46:00 GMT 2025 , Edited by admin on Mon Mar 31 17:46:00 GMT 2025
PRIMARY
Related Record Type Details
GIARDIA LAMBLIA
TARGET ORGANISM->INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 3 (HUMAN)
METABOLIC ENZYME -> SUBSTRATE
TRICHOMONAS VAGINALIS
TARGET ORGANISM->INHIBITOR
IC50
Related Record Type Details
Structure of ALBENDAZOLE SULFONE
METABOLITE INACTIVE -> PARENT
Structure of ALBENDAZOLE OXIDE
METABOLITE ACTIVE -> PARENT
Responsible for activity of albendazole. Less active but predominant form in blood.
BINDING
Related Record Type Details
Structure of METHYL (5-CHLORO-2-BENZIMIDAZOLYL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL N-(4,6-DICHLORO-1H-BENZIMIDAZOL-2-YL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALBENDAZOLE-2-AMINO SULFONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of OXIBENDAZOLE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALBENDAZOLE SULFONE
IMPURITY -> PARENT
sum of impurities B and C: maximum 0.4 percent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALBENDAZOLE AMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALBENDAZOLE-2-AMINO SULFONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL N-(5-((2-METHYL-4-OXOPENTAN-2-YL)SULFANYL)-1H-BENZIMIDAZOL-2-YL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 5-(S-METHYL) ALBENDAZOLE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ALBENDAZOLE OXIDE
IMPURITY -> PARENT
sum of impurities B and C: maximum 0.4 percent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL N-(5-(BUTYLSULFANYL)-1H-BENZIMIDAZOL-2-YL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL N-(5-((PROPAN-2-YL)SULFANYL)-1H-BENZIMIDAZOL-2-YL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CARBENDAZIM
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of ALBENDAZOLE
ACTIVE MOIETY
Converted to ALBENDAZOLE OXIDE rapidly in blood. for parasitic infections of the gastrointestinal tract, it is likely the parent drug has the effect since the S-oxide is generated post-absorption.
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Cmax PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966